Drug Trial Radar · NCT06858579
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Feb 10, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Dianthus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
ClaseprubartDrug
IV Infusion
ClaseprubartDrug
SC injection
PlaceboDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part B: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT)Time frame: Part B baseline to Part B end of treatment period (up to Week 52)
Locations
201 sites in 31 countries. Site status is shown where the registry gives one.
Clinical Study Site
Birmingham, Alabama · Recruiting
Clinical Study Site
Phoenix, Arizona · Recruiting
Clinical Study Site
Scottsdale, Arizona · Recruiting
Clinical Study Site
Los Angeles, California · Recruiting
Clinical Study Site
San Francisco, California · Recruiting
Clinical Study Site
San Francisco, California · Recruiting
Cinical Study Site
New Haven, Connecticut · Recruiting
Clinical Study Site
Washington D.C., District of Columbia · Recruiting
Clinical Study Site
Maitland, Florida · Recruiting
Clinical Study Site
Tampa, Florida · Recruiting
Clinical Study Site
Honolulu, Hawaii · Recruiting
Clinical Study Site
Chicago, Illinois · Recruiting
Clinical Study Site
Edwardsville, Illinois · Recruiting
Clinical Study Site
Indianapolis, Indiana · Recruiting
Clinical Study Site
Kansas City, Kansas · Recruiting
Clinical Study Site
Burlington, Massachusetts · Recruiting
Clinical Study Site
East Lansing, Michigan · Recruiting
Clinical Study Site
Omaha, Nebraska · Recruiting
Cinical Study Site
Lebanon, New Hampshire · Recruiting
Clinical Study Site
New York, New York · Recruiting
Clinical Study Site
New York, New York · Recruiting
Clinical Study Site
Cincinnati, Ohio · Recruiting
Clinical Study Site
Columbus, Ohio · Recruiting
Clinical Study Site
Portland, Oregon · Recruiting
Cinical Study Site
Nashville, Tennessee · Recruiting
Clinical Study Site
Dallas, Texas · Recruiting
Clinical Study Site
Denton, Texas · Recruiting
Cinical Study Site
Houston, Texas · Recruiting
Texas Locations
Houston, Texas · Recruiting
Clinical Study Site
Round Rock, Texas · Recruiting
Clinical Study Site
Sugar Land, Texas · Recruiting
Clinical Study Site
Seattle, Washington · Recruiting
Cinical Study Site #3
Buenos Aires, Argentina · Recruiting
Cinical Study Site #4
Buenos Aires, Argentina · Recruiting
Cinical Study Site
Buenos Aires, Argentina · Recruiting
Clinical Study Site #2
Buenos Aires, Argentina · Recruiting
Clinical Study Site
Buenos Aires, Argentina · Recruiting
Cinical Study Site #2
San Miguel de Tucumán, Argentina · Recruiting
Clinical Study Site
San Miguel de Tucumán, Argentina · Recruiting
Cinical Study Site
Buenos Aires, Buenos Aires, Argentina · Recruiting
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.